ADAR2-mediated editing of RNA substrates in the nucleolus is inhibited by C/D small nucleolar RNAs by Vitali, Patrice et al.
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
Y
 
©
 
 The Rockefeller University Press $8.00
The Journal of Cell Biology, Vol. 169, No. 5, June 6, 2005 745–753
http://www.jcb.org/cgi/doi/10.1083/jcb.200411129
 
JCB: ARTICLE
 
JCB 745
 
ADAR2-mediated editing of RNA substrates in the 
nucleolus is inhibited by C/D small nucleolar RNAs
 
Patrice Vitali,
 
1,3
 
 Eugenia Basyuk,
 
2
 
 Elodie Le Meur,
 
4
 
 Edouard Bertrand,
 
2
 
 Françoise Muscatelli,
 
4
 
 Jérôme Cavaillé,
 
1
 
 
and Alexander Huttenhofer
 
3
 
1
 
Laboratoire de Biologie Moléculaire des Eucaryotes, Centre National de la Recherche Scientiﬁque (CNRS), UMR 5095, Institut Fédératif de Recherche (IFR) 109, 
31062 Cedex Toulouse, France
 
2
 
Institut de Genetique Moleculaire de Montpellier, CNRS, UMR 5535, Université Montpellier II, IFR 122, 34293 Montpellier Cedex 5, France
 
3
 
Innbruck Biocentre, Division of Genomics and RNomics, Innsbruck Medical University, 6020 Innsbruck, Austria
 
4
 
Institut de Biologie du Développement de Marseille, Campus de Luminy, 13288 Cedex 9, Marseille, France
 
osttranscriptional, site-speciﬁc adenosine to inosine
(A-to-I) base conversions, designated as RNA edit-
ing, play signiﬁcant roles in generating diversity of
gene expression. However, little is known about how and
in which cellular compartments RNA editing is controlled.
Interestingly, the two enzymes that catalyze RNA editing,
adenosine deaminases that act on RNA (ADAR) 1 and 2,
have recently been demonstrated to dynamically associ-
ate with the nucleolus. Moreover, we have identiﬁed a
brain-speciﬁc small RNA, termed MBII-52, which was
predicted to function as a nucleolar C/D RNA, thereby
P
 
targeting an A-to-I editing site (C-site) within the 5-HT2C
serotonin receptor pre-mRNA for 2
 
 
 
-
 
O
 
-methylation.
Through the subcellular targeting of minigenes that con-
tain natural editing sites, we show that ADAR2- but not
ADAR1-mediated RNA editing occurs in the nucleolus.
We also demonstrate that MBII-52 forms a bona ﬁde
small nucleolar ribonucleoprotein particle that speciﬁcally
decreases the efﬁciency of RNA editing by ADAR2 at the
targeted C-site. Our data are consistent with a model in
which C/D small nucleolar RNA might play a role in the
regulation of RNA editing.
 
Introduction
 
Primary RNA transcripts can undergo adenosine to inosine
(A-to-I) RNA editing through hydrolytic deamination at the
C-6 atom of adenosine (for reviews see Bass, 2002; Schaub
and Keller, 2002; and Maas et al., 2003). These posttranscrip-
tional RNA processing events are catalyzed by specific en-
zymes called adenosine deaminases that act on RNA (ADARs;
Keller et al., 1999; Bass, 2002). Three structurally related
members of the ADAR family have been characterized:
ADAR1 and 2, which are ubiquitously expressed in many tis-
sues with strong expression in the brain (Wagner et al., 1990);
and ADAR3/RED2, which is only expressed in neuronal tis-
sues and has not been proven to be an active enzyme (Melcher
et al., 1996a; Chen et al., 2000). A-to-I RNA editing occurs
within completely or partially double-stranded (ds) RNA struc-
tures. Sites of A-to-I editing are generally found within non-
coding sequences such as repetitive sequences, introns, and 3
 
 
 
untranslated regions (Morse et al., 2002; Levanon et al., 2004).
However, a few site-specific edited sites have been also detected
within the open reading frame of cellular and viral pre-mRNA
transcripts. Because the newly introduced inosine residue is de-
coded as a guanosine by the translation apparatus, A-to-I RNA
editing has the potential to diversify the genetic information so
that more than one protein is produced from a single gene (Bass,
2002; Schaub and Keller, 2002; Maas et al., 2003; Seeburg and
Hartner, 2003).
In the best understood examples of site-specific A-to-I
RNA editing in mammals, ionotropic glutamate receptors
(GluRs) and serotonin receptors (5-HT2C isoforms), the func-
tional properties of the respective gene products, are modulated
(Sommer et al., 1991; Burns et al., 1997; Seeburg and Hartner,
2003). In the case of GluR, RNA editing at the Q/R site of the
GluR-B subunit of an 
 
 
 
-amino-3-hydroxy-5-methyl-4-isox-
azolepropionate receptor (a Gln codon is changed to an Arg
codon) decreases the Ca
 
2
 
 
 
 permeability of the receptor (Som-
mer et al., 1991; Seeburg, 1996). Another edited site within
GluR-B RNA is the R/G site (an Arg codon is changed to a Gly
codon), resulting in an increase in the rate at which the chan-
nels recover from desensitization (Lomeli et al., 1994). In the
serotonin 5-HT2C receptor pre-mRNA, five closely spaced ed-
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ited adenosines (A–E sites) alter the coding potential of three
codons (see Figs. 1 A and 3 A). By decreasing the efficiency of
G-protein coupling, the RNA editing of 5-HT2C gives rise to
serotonin receptor isoforms with a reduced constitutive activity
(Burns et al., 1997; Herrick-Davis et al., 1999; Niswender et
al., 1999; Berg et al., 2001).
The mechanism and the spatio-temporal regulation of
site-specific RNA editing (Lomeli et al., 1994; Burns et al.,
1997; Barbon et al., 2003; Yang et al., 2004) is still poorly un-
derstood. Most site-specific RNA editing requires a partial
dsRNA structure that involves the exonic sequence encompass-
ing the edited site(s) and a downstream intronic sequence
(Higuchi et al., 1993; Burns et al., 1997). Thus, RNA editing
and RNA splicing might interfere with each other or might
even be coordinated (Higuchi et al., 2000; Wang et al., 2000;
Bratt and Ohman, 2003; Flomen et al., 2004). Accordingly,
ADAR1 and 2 are found to be associated with the spliceosome
in a large nuclear particle, which is consistent with a physical
interaction between editing and splicing machineries (Raitskin
et al., 2001). Cellular annealing and unwinding activities af-
fecting the overall stability of the dsRNA structure, which is
recognized by ADARs, also play key roles to control RNA
splicing and/or RNA editing (Reenan et al., 2000; Bratt and
Ohman, 2003). Regulation of the intracellular levels of ADARs
is expected to affect the overall efficiency of RNA editing
(Kawahara et al., 2003; Yang et al., 2003a). In this line,
ADAR2 is able to edit its own pre-mRNA to create a new 3
 
 
 
splice site, the utilization of which results in a frameshift that
gives rise to a nonfunctional ADAR2 protein. This autonega-
tive feedback loop might regulate the endogenous level of
ADAR2 (Rueter et al., 1999). Surprisingly, the treatment of
mice with fluoxetine (a serotonin re-uptake inhibitor) affects
the RNA editing of 5-HT2C pre-mRNA, suggesting that RNA
editing can be regulated in a serotonin-dependent manner
(Gurevich et al., 2002).
In vivo
 
,
 
 the subnuclear location where A-to-I RNA edit-
ing occurs has not been precisely characterized yet. However,
because RNA editing reactions require the formation of an
RNA duplex formed by base pairing between intronic and ex-
onic sequences, editing has to occur before RNA splicing. Sur-
prisingly, two observations suggest that nucleolar-associated
functions might regulate RNA editing to some extent. First,
ADAR1 and 2 are dynamically associated with the nucleolus,
and, although a functional role of the nucleolus in the editing
process is far from being understood, it has been proposed that
nucleolar sequestration of the editing enzymes modulates RNA
editing (Desterro et al., 2003; Sansam et al., 2003; Yang et al.,
2003b; Nie et al., 2004). Also, we have previously identified a
brain-specific C/D RNA, designated as MBII-52, that is pre-
dicted to target an A-to-I editing site within the 5-HT2C seroto-
nin receptor mRNA for 2
 
 
 
-
 
O
 
-methylation of the ribose of the
edited base. In mammals, site-specific 2
 
 
 
-
 
O
 
-methylations of
rRNAs (ribosomal RNAs) and U spliceosomal RNAs are di-
rected by C/D RNAs, with most of them accumulating and
functioning in the nucleolus (hence their designation as small
nucleolar RNAs [snoRNAs]) and a few of them in the Cajal
bodies (CBs; hence their designation as small CB-specific
RNAs [scaRNAs]; Kiss, 2002). These C/D RNAs act through
the formation of a canonical RNA duplex in which the nucle-
otide to be 2
 
 
 
-
 
O
 
-methylated in the target RNA is paired to the
fifth position upstream from the conserved D (or D
 
 
 
) box se-
quence motif found in all of the C/D small RNA (Cavaillé et
al., 1996; Kiss-Laszlo et al., 1996). Importantly, the nucleotide
that is predicted to be modified by MBII-52 C/D RNA is pre-
cisely the edited C-site within 5-HT2C pre-mRNA. A 2
 
 
 
-
 
O
 
-
methylation of the ribose of an adenosine nucleotide has been
shown to specifically decrease the deamination rate of the
modified adenosine in vitro (Yi-Brunozzi et al., 1999); thus, by
its antisense element, MBII-52 is predicted to negatively regu-
late pre-mRNA editing at the C-site (Cavaillé et al., 2000).
In this study, we designed several experiments to address
unresolved questions regarding the potential involvement of the
nucleolar compartment in the control of site-specific RNA edit-
ing. Thereby, we wanted to specifically address the following
points: (1) Are editing enzymes ADAR1 and 2 functional within
the nucleolus? (2) Is MBII-52 a bona fide C/D methylation
snoRNA guide? And (3) does expression of MBII-52 snoRNA
affect RNA editing at the C-site of a 5-HT2C RNA substrate?
 
Results
 
ADAR2, but not ADAR1, can edit 
nucleolar 5-HT2C and GluR-B 
dsRNA substrates
 
Several groups have recently reported that endogenous
ADAR1 and 2 display a dynamic nucleolar association, with
ADAR2 shuttling between the nucleolus and the nucleoplasm
and ADAR1 shuttling between the nucleolus, the nucleoplasm,
and the cytoplasm (Desterro et al., 2003; Sansam et al., 2003;
Yang et al., 2003b; Nie et al., 2004). Although the functional
significance of these observations is unknown, it has been pro-
posed that RNA editing might be regulated by the intracellular
compartmentalization of these ADARs (Desterro et al., 2003;
Sansam et al., 2003). To investigate whether ADARs are ac-
tive within the nucleolus, we analyzed RNA editing within
a 5-HT2C dsRNA substrate (A–E-sites) and two GluR-B
dsRNA substrates (Q/R and R/G sites), transcribed either from
a cytomegalo virus (CMV) promoter (Pol II) or a ribosomal
gene promoter (Pol I; Fig. 1, A and B). We reasoned that the
distinct subcellular location expected for Pol II and Pol I tran-
scripts (i.e., in the nucleoplasm and the nucleolus, respec-
tively; Fig. 1 C) allows discrimination between nucleolar and
nucleoplasmic RNA editing. Indeed, previous studies have
shown that the majority of Pol I transcripts do not leave the nu-
cleolus to a large extent (Cavaillé et al., 1996; Ganot et al.,
1999; Jady et al., 2003). Pol I– and Pol II–5-HT2C minigenes
were, therefore, transiently transfected into NIH-3T3 (which
contains low levels of endogenous editing activities) together
with either hADAR1- or hADAR2-expressing vectors. RNA
editing efficiency was measured at each edited site by direct
sequencing of the RT-PCR products (Fig. 2 A). Consistent
with earlier reports (Burns et al., 1997; Higuchi et al., 2000;
Hartner et al., 2004), when nucleoplasmic RNA editing was
assayed, we observed that RNA editing at the D-site is mainly 
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catalyzed by ADAR2, whereas ADAR1 preferentially edits the
A- and B-sites; E- and C-sites are catalyzed by both enzymes
(Fig. 2 A). In the course of this work, we also detected a novel
edited site: the G-site edited by ADAR2 (Fig. 2 A), which
maps within an intronic segment that base pairs with the ex-
onic sequence containing the A–E-sites (Fig. 1 A). Intrigu-
ingly, this novel edited site was not detected in total RNA that
was extracted from mouse brains (unpublished data); thus, its
biological relevance is questionable.
Surprisingly, when nucleolar RNA editing was assayed,
only adenosines at the D- and G-sites (edited by ADAR2) were
found to be significantly converted into inosines (58.01 
 
 
 
4.6% and 15.3 
 
 
 
 3.2%, respectively), whereas A- and B-sites
(edited by ADAR1) remained fully unedited. Nevertheless, se-
quencing of the cloned RT-PCR products obtained from the
same transfection experiments indicated that 
 
 
 
5% of the C-site
was edited by ADAR2 in the nucleolus (unpublished data).
Therefore, we reanalyzed RNA editing at the C-site by the
more sensitive primer extension method (Burns et al., 1997).
As shown in Fig. 2 A (right), nucleolar RNA editing mediated
by ADAR2 is readily detected at the C-site (3.9 
 
  
 
0.63%) and
also at the E-site, albeit at very low levels.
We also tested whether nucleolar RNA editing can occur
at the Q/R and R/G edited sites in GluR-B dsRNA substrates.
Again, we found that the Q/R site (only edited by ADAR2
[Higuchi et al., 2000]) as well as the R/G site (edited by
ADAR1 and 2 [Maas et al., 1996; Melcher et al., 1996a,b]) are
efficiently deaminated by ADAR2 in either Pol II or Pol
I/GluR-B transcripts (efficiency of editing at Q/R and R/G sites
in the Pol I transcripts is 40.1 
 
 
 
 2.65% and 49.85 
 
 
 
 13%, re-
spectively; Fig. 2 B). In contrast, ADAR1 faithfully edits the
R/G site in the Pol II/GluR-B dsRNAs, but not within Pol I
transcripts, because it is targeted to the nucleolus (Fig. 2 B).
Thus, we conclude that ADAR2 is active within the nucleolar
compartment, whereas ADAR1 is not.
Given that Desterro et al. (2003) recently reported that an
NH
 
2
 
-terminal deletion mutant of ADAR1 (lacking aa 1–442),
termed GFP-ADAR1C-Term, is exclusively targeted to the nu-
cleolus, we tested its ability to be active in RNA editing. Again,
although the truncated GFP-ADAR1C-Term protein can edit
the A- and B-edited sites as well as the R/G site in a Pol II–
transcribed dsRNA substrate, no RNA editing could be de-
tected within the same Pol I–transcribed dsRNA (Fig. 2 C). As
controls, we monitored the distribution of the transfected GFP-
tagged versions of ADAR2 and ADAR1C-Term. In agreement
with an earlier report (Desterro et al., 2003), the two GFP-
tagged proteins were mainly detected within the nucleolus (Fig.
2 D). Altogether, these data indicate that although both GFP-
ADAR1C-Term and ADAR2-GFP proteins are detected in the
nucleolus, only ADAR2 is able to efficiently edit a dsRNA
structure within this organelle. It is noteworthy that endoge-
nous levels of ADAR2 in NIH-3T3 do not support an efficient
nucleolar RNA editing (Fig. 2 A, right). This is in contrast to
the neuroblastoma cell line Neuro2A (unpublished data), sug-
gesting that the intracellular level of endogenous ADAR2 pro-
tein might be critical for the nucleolar activity of the enzyme.
 
MBII-52 exhibits all of the functional 
properties of a C/D nucleolar methylation 
RNA guide 
 
In addition to a potential role of the nucleolus in sequestering
ADAR1 and 2 activities (Desterro et al., 2003; Sansam et al.,
2003) and/or representing one of the nuclear sites of ADAR2-
mediated RNA editing (Fig. 2), nucleolar-associated functions
might also be required to fine tune RNA editing in a sequence-
specific manner. Consistent with that assumption, MBII-52 (a
C/D small RNA) displays a long antisense element matching a
nucleotide tract within 5-HT2C pre-mRNA. This undergoes
both alternative splicing (Canton et al., 1996; Wang et al.,
2000) and A-to-I RNA editing (Burns et al., 1997), thus raising
the possibility that this small RNA might control 5-HT2C ex-
pression (Cavaillé et al., 2000; Fig. 3 A). To get better insight
into that hypothesis, we first asked whether this C/D RNA be-
longs to the snoRNA that accumulates within the nucleolus or
Figure 1. Differential subnuclear locations of Pol I– and Pol II–derived transcripts. (A) RNA stem-loop structure of 5-HT2C formed by exon V (bold characters)
and intron 5. Exonic (A–E) and intronic (G; this study) editing sites are underlined, and ADARs specificity is mentioned. 12 indicates the size (in nucleotides)
of the bulge. (B) Schematic representation of Pol I/5-HT2C and Pol II/5-HT2C constructs. (C) Pol I/5-HT2C and Pol II/5-HT2C constructs give rise to RNAs
that accumulate in the nucleolus and in the nucleoplasm, respectively. In situ hybridization was performed with Cy3-labeled oligonucleotide probes comple-
mentary to Pol I and Pol II/5-HT2C RNAs. U3 snoRNA was detected with a Cy5-labeled oligonucleotide probe and was used as a nucleolar marker. 
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to the scaRNA, a recently identified class of C/D RNAs that are
only detected within the CBs (Kiss, 2002). In situ hybridiza-
tions with specific Cy3-labeled fluorescent oligonucleotide
probes against MBII-52 was performed on adult rat brain sec-
tions. As shown in Fig. 3 B (left), MBII-52–specific signals
merge perfectly with those of U3 C/D snoRNA, which is
known to reside in the nucleolus. In addition, in many cells,
this probe also gives rise to a more punctate nucleoplasmic sig-
nal outside the nucleolus (Fig. 3 B, right) that has been identi-
fied as CBs based on colocalization with coilin, a marker of
this nuclear body. Note that MBII-85 is present in the nucleolus
of the cell as well (Fig. 3 B). Immunoprecipitation performed
from a rat brain total extract also reveals that these two C/D
RNAs interact with three common C/D RNA-binding proteins:
namely, fibrillarin, NHPX, and NOP58 (Fig. 3 C).
We next examined whether MBII-52 can act as an RNA
methylation guide by expressing a predicted, minimal RNA tar-
get (Fig. 3 A). A short fragment that was complementary to the
antisense elements of MBII-52 was placed under the transcrip-
tional control of a Pol I promoter (Pol I-52 target), which allows
specific targeting of the RNA substrate to the nucleolus (Ca-
vaillé et al., 1996; Fig. 1). The plasmid construct was tran-
siently transfected into NIH-3T3 cells in the presence or absence
of an MBII-52–expressing vector. The presence of the targeted
2
 
 
 
-
 
O
 
-methylation was then assayed by primer extension analy-
sis, as described previously (Maden, 2001). As shown in Fig.
3 D, a deoxynucleotide triphosphate (dNTP) concentration-
dependent pause of reverse transcriptase was mapped at the
expected nucleotide only in total RNA that was extracted from
NIH-3T3 cotransfected with MBII-52–expressing plasmids. The
same vector was also introduced into Neuro2A cells, a neuro-
blastoma cell line that endogenously expresses MBII-52, albeit
at low levels (unpublished data); again, the same dNTP concen-
tration-dependent pause pattern was observed. We conclude that
the endogenously expressed MBII-52, as well as MBII-52 ex-
pressed from a transfected plasmid, can direct a sequence-
specific 2
 
 
 
-
 
O
 
-methylation into an RNA target. Hence, MBII-52
can be considered as a bona fide methylation guide C/D snoRNA.
 
Partial coexpression of MBII-52 and 
5-HT2C serotonin receptor mRNA in the 
adult mouse brain 
 
A prerequisite for the in vivo role of MBII-52 in the editing of
5-HT2C receptor pre-mRNA is to show the coexpression of
Figure 2. Transfected hADAR2, but not transfected hADAR1 or ADAR1C-Term, is functional in the nucleolus. Histograms show the percentage of RNA editing
at each edited adenosine after transient transfection in NIH-3T3 cells with the indicated constructs (A–C). Values represent the mean of three independent
experiments (n   3; error bars represent SD). Note: because the Q/R site of GluR-B is specifically edited by ADAR2, the editing efficiency of Pol I and
Pol II/GluR-B (Q/R) upon ADAR1 transfection was not determined (ND). (A, right) Primer extension analysis of RNA editing at the C- and D-sites. The
nucleotide sequence of the 5  end-labeled (
32P) oligonucleotide sense primer, the antisense strand of the RT-PCR template, and the positions of the editing
sites are indicated. P, primer. (D) Subcellular localization of GFP-ADAR2 and GFP-ADAR1C-Term in transiently transfected NIH-3T3. Nucleoli are visualized
by a fluorescent oligonucleotide probe (Cy5) directed against U3 snoRNA. 
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both transcripts in the same brain regions. Thus, we performed
in situ hybridization on adjacent sections of adult mouse brains
with probes specific for MBII-52 and 5-HT2C receptor pre-
mRNA to compare their expression patterns. To reveal trace
levels of serotonin 5-HT2C expression (which could not have
been detected with a 5-HT2C receptor antisense ribobrope), we
also used a probe for the H/ACA snoRNA MBI-36. This small
RNA is specifically encoded within intron 2 of 5-HT2C pre-
mRNA (Fig. 3 A) and accumulates as a stable product concen-
trated in the nucleus; thus, it was easily detected. MBII-52 is
expressed only in neurons of a broad variety of adult mouse
brain structures—including the dentate gyrus; CA1, CA2, and
CA3 in the hippocampus, granular cell layer, mitral cell layer,
and glomerular cell layer in the olfactory bulb; or Purkinje cells
in the cerebellum (unpublished data)—but is never expressed
in the choroids plexus, whereas the 5-HT2C receptor and MBI-
36 are expressed within this structure (Fig. 4, A–C). This is
consistent with earlier reports (Molineaux et al., 1989; Cavaillé
et al., 2000). However, among some structures where MBII-52
is expressed, we also detected an expression of 5-HT2C and
MBI-36 (Fig. 4, D–L). Indeed, in the subthalamic nucleus
(Fig. 4, D–F) and the piriform cortex (Fig. 4, G–I), MBII-52,
5-HT2C receptor, and MBI-36 display relevant, overlapping
expression patterns. In some other brain structures, such as the
medial and lateral parts of the geniculate nuclei, MBII-52,
5-HT2C receptor, and MBI-36, expression patterns partially
overlap with a more restricted expression of 5-HT2C receptor
(Fig. 4, J–L). These results are consistent with the ability of
MBII-52 to play a role in the processing of 5-HT2C pre-mRNA
in the neurons of some adult brain structures.
 
Nucleolar, but not nucleoplasmic, RNA 
editing can be specifically inhibited by a 
targeted C/D snoRNA 
 
Although it is an attractive model, the in vivo involvement of
MBII-52 in the posttranscriptional regulation of 5-HT2C pre-
mRNA expression is difficult to formally prove because: (1) no
classical methodology is sensitive enough to reliably identify
2
 
 
 
-
 
O
 
-methylated nucleotides in low-abundance RNA; (2) the
transient nature of the in vivo interaction between C/D RNA
and its RNA target hampers the use of classical biochemical ap-
proaches; and (3) no easily tractable cell lines express MBII-52
and 5-HT2C genes at levels comparable with those found in
brain tissues (unpublished data). We next asked whether the ex-
pression of C/D snoRNAs bearing an antisense element that is
designed to target an adenosine to be edited can interfere with
its deamination level, as proposed by the model that MBII-52
snoRNA targets 5-HT2C pre-mRNA. To test this possibility,
Figure 3. MBII-52 is a bona fide C/D box snoRNA. (A, top) Structure of the mouse serotonin receptor 5-HT2C gene. The exon V segment, including the
alternative 5  splice site and the edited sites (A–E-sites), are indicated by a black box, whereas the MBI-36 H/ACA box RNA gene that is encoded within
the second intron is shown by a black ellipse (not drawn to scale). (bottom) Predicted base pairing between MBII-52 and 5-HT2C–pre-mRNA. The edited
C-site predicted to be targeted by MBII-52 is located at the fifth nucleotide upstream from the D-box. The alternative 5  splicing site is boxed. The editing
sites A–E are underlined, and the corresponding amino acid changes in the receptor encoded by the edited and unedited mRNAs are indicated. (B) MBII-52
and MBII-85 can be detected both in the nucleolus and in CBs. (left) In situ hybridization from adult rat brain sections by using specific fluorescent oligonu-
cleotide probes against RBII-52 (Cy3), RBII-85 (Cy3), and U3 C/D snoRNA as a nucleolar marker (Cy5). (right) Same probes were used, except that coilin
was used as a CBs marker (immunodetection with anticoilin antibodies). White arrowheads indicate the position of CBs. (C) MBII-52 and MBII-85 C/D
RNA associate with NHPX, fibrillarin, and NOP58. Immunoprecipitation was performed from whole rat brain extracts as previously described (Cavaillé et
al., 2001) with anti-NHPX R86, anti-NOP58, and antifibrillarin 72B9. RBII-52 and RBII-85 were detected by Northern blot hybridization with specific
32P-labeled oligonucleotide probes. 5.8 S rRNA was used as a negative control. I, input (1/10); P, pellet; S, supernatant. (D) Endogenous as well as trans-
fected MBII-52 C/D RNA can direct a sequence-specific 2 -O-ribose methylation only on an RNA target to the nucleolus. NIH-3T3 and Neuro2A cells were
transiently transfected as indicated, and the ribose 2 -O-methylated nucleotide was mapped by the primer extension assay method (Maden, 2001).
The arrow denotes the position of the dNTP concentration–dependent pause of reverse transcriptase. 
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we first cotransfected either the Pol II/ or Pol I/5-HT2C vector
in the presence or absence of an MBII-52 snoRNA-expressing
vector into the NIH-3T3 cell line. In addition, cells were
cotransfected with a plasmid expressing ADAR2 (Fig. 5 A). Al-
though the expression of MBII-52 does not significantly affect
RNA editing at the D- and C-sites in Pol II/5-HT2C RNA, we
observed a very substantial decrease at the C-site (51.3 
 
 
 
 1.3%)
in the Pol I/5-HT2C transcript. Editing at the D-site was un-
changed. We also showed that an artificial snoRNA (termed
 
 
 
-D snoRNA) carrying an antisense element directed against
the D-site (Fig. 5 A, top) can specifically affect deamination
levels at this site, but only when its target was transcribed within
the nucleolus (a decrease of 37.8 
 
 
 
 2%). Finally, the targeting
of other artificial C/D snoRNAs (Fig. 5 B, top) against the Q/R
or R/G sites within GluR-B dsRNA substrates also resulted in a
significant decrease in the nucleolar editing (49 
 
 
 
 5.5% and 56 
 
 
 
6.2%, respectively), whereas nucleoplasmic editing was unaf-
fected (Fig. 5 B). In all of these experiments, all transfected
C/D snoRNAs were only detected within the nucleolus and were
found to be expressed at the same levels as judged by Northern
blot analysis (unpublished data). From these data, we conclude
that MBII-52 as well as artificial C/D snoRNAs have the poten-
tial to inhibit RNA editing within the nucleolar compartment.
 
Discussion
 
In recent years, it has become evident that gene expression in
eukaryotes is linked to spatial nuclear compartmentalization
(Carmo-Fonseca, 2002; Chubb and Bickmore, 2003). One of
the best known examples is the nucleolus, which plays a key
role in ribosome biogenesis as well as in a broad range of cellu-
lar processes, RNA-processing steps, and nuclear functions
(Olson et al., 2002). The nucleolus is a nonmembrane-bound
nuclear structure, and although its organization is not com-
pletely understood, recent studies lead to the view that there is
a constant flux of molecules between the nucleolus and its sur-
rounding nucleoplasmic environment (Phair and Misteli, 2000;
Andersen et al., 2005). In this line, ADARs, the enzymes that
catalyze A-to-I RNA editing, display a complex subcellular
compartmentalization, with ADAR2 being localized in the nu-
cleolus as well as in the nucleoplasm, whereas ADAR1 locates
throughout the nucleolus, nucleoplasm, and cytoplasm (Des-
terro et al., 2003; Sansam et al., 2003; Yang et al., 2003b; Nie
et al., 2004). Photobleaching experiments indicate that ADARs
are constantly and rapidly shuttling in and out of the nucleolus
(Desterro et al., 2003; Sansam et al., 2003). Furthermore, upon
the transfection of a Pol II transcript–containing edited site,
both ADAR1 and 2 are excluded from the nucleoli, and this
translocation step is correlated with an increased RNA editing
in the nucleoplasm (Desterro et al., 2003; Sansam et al., 2003).
Overall, these data show that the nucleolar association of
ADAR enzymes is transient, and the nucleolar environment
might merely represent a storage compartment rather than a
functional site of RNA editing. However, the RNA editing
activities of nucleolar-localized ADAR enzymes have not
been determined until now. Through a specific targeting
strategy of dsRNA substrates to the nucleolus (Figs. 1 and 2),
we showed that ADAR2- but not ADAR1-mediated RNA editing
can occur in the nucleolus, raising the possibility that endog-
enous cellular and/or viral transcripts might be edited within
this subnuclear compartment.
The inability of ADAR1 to perform nucleolar RNA edit-
ing is unexpected and deserves several comments. Because
human ADAR1 and 2 localize in the same subnucleolar com-
partment (Desterro et al., 2003), a subtle differential intranu-
cleolar distribution between these two enzymes is unlikely to
account for differences in their nucleolar editing activities.
ADAR1 exhibits unique features compared with other ADAR
enzymes, including two Z-DNA–binding protein domains and
an additional (third) dsRNA-binding domain. Thus, ADAR1-
mediated RNA editing might require strict coupling with the
nucleoplasmic environment and/or with the transcribing Pol II
apparatus. In this line, ADAR1 in 
 
Xenopus laevis 
 
associates
with transcriptionally active lampbrush chromosomes, sug-
gesting that RNA editing by ADAR1 might occur cotranscrip-
tionally (Doyle and Jantsch, 2003). We also cannot rule out
the possibility that ADAR1 is posttransductionally modified
in the nucleolus, thus rendering it inactive (J. Desterro, personal
communication). Finally, the nucleolar form of ADAR1 might
be linked to other functions that are not directly related to
RNA editing.
Figure 4. Partial coexpression of MBII-52 and 5-HT2C receptor transcripts
in adult mouse brains. In situ hybridization on sagittal and adjacent sec-
tions of adult mouse brains confirms that 5-HT2C (B) and MBI-36 (C) are
highly expressed in choroids plexus, whereas MBII-52 (A) is not, and also
reveals coexpression of MBII-52 (D, G, and J) and 5-HT2C receptor tran-
scripts (E, H, and K) in other discrete regions of adult brains. The snoRNA
MBI-36 (F, I, and L), which is present within intron 2 of the 5-HT2C recep-
tor, allows confirmation of the expression pattern of 5HT-2C pre-mRNA.
MBII-52, 5-HT2C receptor, and MBI-36 are coexpressed in the subtha-
lamic nucleus (D–F), in the piriform cortex (G–I), and in the medial and
lateral parts of the geniculate nuclei (J–L). CPL, choroid plexus; STh, sub-
thalamic nucleus; Pir, piriform cortex; DLG, dorsal lateral geniculate nuclei;
MGD, medial geniculate nucleus, dorsal part; MGV, medial geniculate
nucleus, ventral part. 
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Another objective of this study was to investigate the
functional relevance of the putative MBII-52/5-HT2C interac-
tion, specifically its capacity to interfere with RNA editing. By
localization and associated protein-binding partners, MBII-52
is a bona fide methylation guide C/D snoRNA (Fig. 3) that dis-
plays a partially overlapping expression pattern with its puta-
tive RNA target in some regions of the adult mouse brain (Fig.
4). Remarkably, our study shows that MBII-52 RNA con-
structs and artificial C/D snoRNAs reduce ADAR2-mediated
nucleolar editing of an RNA substrate in a sequence-specific
manner (Fig. 5), whereas nucleoplasmic RNA editing remains
unaffected. Artificial C/D snoRNAs have been previously re-
ported to target 2
 
 
 
-
 
O
 
-methylations at ectopic positions in rRNAs
or in artificial RNAs (Cavaillé et al., 1996; Kiss-Laszlo et al.,
1996; Liu and Fournier, 2004), but to our knowledge our study
represents the first demonstration that expression of a cognate
C/D snoRNA inhibits a specific RNA processing event in
mammalian cells. Together, our results are consistent with a
model in which MBII-52 has the potential to inhibit RNA edit-
ing in vivo.
We are making the assumption that endogenously ex-
pressed 5-HT2C pre-mRNA might be targeted by MBII-52,
resulting in decreased RNA editing at the cognate C-site of
pre-mRNA. This interaction might eventually fine tune the
G-protein coupling of the encoded serotonin 5-HT2C receptor.
Indeed, the edited C-site plays (together with the E-site) a piv-
otal role in regulating serotonergic signal transduction (Burns
et al., 1997; Niswender et al., 1999; Wang et al., 2000; Gure-
vich et al., 2002). Our model implies an at least transient local-
ization of 5-HT2C pre-mRNA in the nucleolus. How this
would be achieved is not addressed in this study. It is noteworthy,
however, that pre-mRNA splicing can sometimes be uncoupled
from cotranscriptional events and can occur away from the
transcription sites (Lopez and Seraphin, 2000). In addition,
5-HT2C pre-mRNA hosts an H/ACA snoRNA within intron 2
(Fig. 3 A), which could promote the targeting of intron-con-
taining pre-mRNA to the nucleolus (a mechanism previously
observed in plants; Shaw et al., 1998). In vivo interaction be-
tween MBII-52 and its putative RNA target is likely to be
complex and could involve distinct cellular regulatory path-
ways, according to the brain regions in which both transcripts
are expressed (Fig. 4). Thus, at this point, we cannot rule out
the alternative possibility (e.g., that under some circumstances
not mimicked by our experimental transfection assay) that
MBII-52 C/D small nucleolar ribonucleoprotein particles
might have the ability to function outside of the nucleolus.
The human homologues of MBII-52 genes are encoded at
the imprinted 15q11-q13 chromosomal region. This locus is as-
sociated with the Prader-Willi syndrome (PWS), which is a
neurobehavioral disorder characterized by a complex pheno-
type, including hyperphagia and behavioral problems with ob-
sessive compulsive disorder (Nicholls and Knepper, 2001). Al-
though the lack of expression of HBII-52 genes is not sufficient
to result in PWS (Runte et al., 2005), it is noteworthy that a
knockout mice model for 5-HT2C genes leads to epilepsy, to
eating disorders as a result of abnormal control over feeding
behavior (Tecott et al., 1995), and to compulsive behavior
symptoms (Chou-Green et al., 2003) that are described in PWS
patients. Hence, it is tempting to speculate that defects of HBII-
52 expression, which are presumably associated with the lack
of expression of additional paternally expressed genes, might
contribute to some aspects of the PWS disease.
Figure 5. Specific inhibition of ADAR2-mediated nucleolar RNA editing by MBII-52 or artificial C/D snoRNAs. (A and B, top) Canonical base pairing models
between the transfected C/D snoRNAs and their RNA targets. Nucleotides that are potentially targeted by these snoRNAs are underlined and indicated
in bold. (A, bottom) Primer extension analysis of RNA editing performed on total RNA extracted from NIH-3T3 cells transfected with the plasmids indicated
below. Experiments (n   3) were performed as described in Fig. 2 A, and only a representative autoradiogram is shown (in the case of Pol I transcript, two
different time exposures of the same gel are shown for the D-site). Quantification data are indicated in the text. It is noteworthy that in the primer extension
assay, RNA species edited at both C- and D-sites cannot be detected, and, thus, deamination efficiency at the D-site was determined by direct sequencing
of RT-PCR products as described in Fig. 2 A. P, primer. (B, bottom) Histograms showing percentage of RNA editing at the Q/R and R/G sites were deter-
mined by the direct sequencing of RT-PCR products obtained from NIH-3T3 that was transiently transfected by the plasmids as indicated below. 
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Materials and methods
 
Unless otherwise noted, all techniques for cloning and manipulating nucleic
acids were performed according to standard protocols.
 
Oligonucleotides
 
Modified and unmodified oligonucleotides were synthesized by Y. de
Préval (Laboratoire de Biologie Moléculaire des Eucaryotes, Toulouse,
France) on a PerSeptive Biosystems Expedite apparatus or at the MWG
Biotech AG.
 
Plasmid constructs
 
5-HT2C and GluR-B dsRNA substrates were PCR amplified from rat and
mouse genomic DNA, respectively, and were cloned into pW, a riboso-
mal minigene (Cavaillé et al., 1996), to generate Pol I/5-HT2C, Pol
I/GluR-B (Q/R), and Pol I/GluR-B (R/G) vectors. The same PCR products
were also inserted under the control of a CMV promoter into pcDNA 3.1
(Invitrogen) to generate Pol II/5-HT2C, Pol II/GluR-B (Q/R), and Pol II/
GluR-B (R/G). Minigene Pol I-52 target was derived from pW by inserting
a synthetic 20-bp DNA sequence of 5HT2C (Fig. 3 A, underlined se-
quence). pCMV snoRNA 
 
 
 
-D, pCMV snoRNA 
 
 
 
-Q/R, and pCMV snoRNA
 
 
 
-R/G were all derived from pCMV–MBII-52 vectors (Cavaillé et al.,
2000). The mammalian expression vector constructs of hADAR1 (pCS2-
FLIS6-hADAR1) and hADAR2 (pCS2-FLIS6-hADAR2a) were gifts from W.
Keller (Biozentrum, Basel, Switzerland), and expression vector GFP-
ADAR2 and GFP-ADAR1C-Term were provided by M.
 
 
 
Carmo-Fonseca (In-
stitute of Molecular Medicine, Lisboa, Portugal).
 
Cell cultures and transfections
 
The murine NIH-3T3 and Neuro2A cells were cultured as monolayers in
DME (GIBCO BRL) supplemented with 10% FBS (GIBCO BRL) at 37
 
 
 
C and
10% CO
 
2
 
. DNA for transfection assays was purified using a plasmid
maxiprep kit (QIAGEN). Subconfluent cells (
 
 
 
80% of confluency) were
transiently transfected (DAC-30 reagent; Eurogentec) with 500 ng dsRNA
substrates expressing plasmids and 4 
 
 
 
g C/D snoRNA-expressing vectors
or 4 
 
 
 
g of empty pcDNA 3.1 (
 
 
 
) for negative controls.
 
Detection of ribose-methylated nucleotides
 
2
 
 
 
-
 
O
 
-ribose methylation was analyzed by reverse transcription by using
low dNTP concentrations as described in Maden (2001), except that the
lowest concentration was 0.01 mM dNTPs.
 
Analysis of RNA editing
 
48 h after transfection, total RNA was extracted using the TRIzol reagent
(Invitrogen) according to the manufacturer’s protocol. Direct sequencing of
RT-PCR products was performed using the BigDye terminator cycle se-
quencing reaction kit (PE Corp.) and was analyzed on a sequencer
(model ABI Prism 377; PerkinElmer) using the Lasergene sequence analy-
sis program package. Editing efficiency was quantified by measuring the
height of peaks A (no edited site) and G (edited site) in order to determine
the G/A 
 
 
 
 G peak ratio. This ratio was then reported to 100 to determine
the percentage of editing at each site. All transfections were indepen-
dently repeated three times to evaluate the SD. Primer extension assay
was also performed as described in Burns et al. (1997) in the presence of
0.2 mM dATP, dCTP, and dTTP and 0.8 mM ddGTP and Taq polymerase
(
 
n
 
 
 
 
 
 50 cycles). Reactions were analyzed by gel electrophoresis on a
15% polyacrylamide gel, and intensities of the bands were quantified by
PhosphoImager (model FLA-3000; Fujifilm). RNA editing levels at the C-sites
were determined by calculating the ratio of band intensity for each site to
the sum of the three band intensities.
 
In situ hybridization
 
FISH on fixed cells or rat brain sections was performed as described in
Verheggen et al. (2002) by using oligonucleotide-specific probes for Pol
I/5HT2C RNA, Pol II/5HT2C RNA, snoRNA MBII-52 and snoRNA MBII-85
(labeled with Fluorolink Cy3; Amersham Biosciences) and the U3-specific
modified oligonucleotide with Fluorolink Cy5 (Amersham Biosciences).
Nuclear DNA was stained by DAPI. Colorimetric in situ hybridization was
performed on adult brains of C57BL/6 mice purchased from Iffa Credo as
described in Tiveron et al. (1996). 5-HT2C receptor riboprobe (225 bp)
hybridized to the coding sequence of 5-HT2C receptor mRNA (nt 1060–
1284 from GenBank/EMBL/DDBJ under accession no. NM_008312).
MBI-36 and MBII-52 riboprobes were synthetized from pUC18 plasmids,
and an 88-bp-long fragment of MBI-36 and a 77-bp-long fragment of
MBII-52 were cloned, respectively. Probes were labeled with digoxigenin
and were revealed with an antidigoxigenin antibody conjugated with AP.
All results were observable through either a microscope (model Axiophot;
Carl Zeiss MicroImaging, Inc.) with plan neofluar Ph1 10
 
 
 
/0.30 objec-
tive lenses or a microscope (model DMRA; Leica) with Leica 100
 
 
 
 plan
Apo 1.4. The Axiophot microscope was equipped with a camera (model
Dxm1200; Nikon) and Nikon ACT1 acquisition software, whereas the
DMRA microscope was equipped with a camera (model CoolSNAPfx;
Roper Scientific) and Metamorph acquisition software.
 
Immunoprecipitation, immunostaining, and antibodies
 
C/D small nucleolar ribonucleoprotein particle immunoprecipitations from
rat brain extracts have been performed as described in Cavaillé et al.,
(2001) with monoclonal antifibrillarin 72B9 (a gift of M. Pollard, W.M.
Keck Autoimmune Disease Center, La Jolla, CA), rabbit anti-NHPX R86
(a gift of L.B. Chen, Harvard University, Boston, MA), and anti-NOP58
(a gift of R. Luhrmann, Max-Planck-Institute of Biophysical Chemistry, Gottin-
gen, Germany). Immunostaining on rat brain sections have been carried out
as described in Cavaillé et al. (2001) with a polyclonal anticoilin antibody
(diluted 1:100; a gift of A. Lamond, Wellcome Trust Biocentre, Dundee, UK).
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